EU IVDR: Class C IVD Devices Face 2026 Compliance Deadlines

In vitro diagnostic manufacturers are approaching an important milestone under the European Union’s In Vitro Diagnostic Regulation (IVDR). By May 26, 2026, Class C IVD devices must comply with the new IVDR requirements, marking the end of the transition period for this category. This deadline will affect many moderate-risk tests, including infectious disease assays, companion diagnostics, and genetic tests.

Manufacturers that currently hold legacy CE certificates under the old In Vitro Diagnostic Directive (IVDD) must transition their products to the IVDR framework by this date. To remain on the EU market, these companies need to submit applications to a Notified Body, update their technical documentation, and demonstrate compliance with stricter performance evaluation and post-market surveillance requirements.

The IVDR significantly raises the bar for evidence and documentation. It requires continuous performance evaluation, clinical evidence, and a proactive approach to risk management. The role of Notified Bodies has expanded, and the number of available bodies remains limited, which means companies that delay their submissions may face review backlogs and potential market interruptions.

To stay on track, manufacturers should complete gap assessments and engage with Notified Bodies as early as possible in 2025. Updating labeling, data management systems, and vigilance reporting processes will also be necessary to meet the 2026 expectations. For companies that operate globally, aligning IVDR compliance efforts with FDA or other international requirements can help streamline regulatory operations.

Class C IVD manufacturers cannot afford to wait. The 2026 compliance deadline represents a pivotal moment for market access and regulatory credibility in Europe. Those that act now will be positioned to maintain business continuity and build stronger, more resilient quality systems for the future.

If your organization needs expert support in preparing for IVDR compliance or coordinating submissions to your Notified Body, PRP Compliance can help you achieve full readiness before the 2026 deadline.